专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08288341B2 Control of radiation injury 有权
标题翻译：辐射伤害控制
公开(公告)号：US08288341B2
公开(公告)日：2012-10-16
申请号：US12460317
申请日：2009-07-15
申请人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
发明人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
IPC分类号： A61K38/06 , A61K38/07 , A61K38/08
CPC分类号： A61K9/0019 , A61K38/08
摘要： Methods of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide consisting of an amino acid molecule selected from the group consisting of VVC, LAG, AQG, LQGV, QVVC, MTRV, LAGV, LQAV, PGCP, VGQL, RVLQ, EMFQ, AVAL, FVLS, NMWD, LCFL, FSYA, FWVD, AFTV, LGTL, QLLG, YAIT, APSL, ITTL, QALG, GVLC, NLIN, SPIE, LNTI, LHNL, CPVQ, EVVR, MTEV, EALE, EPPE, LGTL, VGGI, RLPG, LQGA, LCFL, TLAVE, VEGNL, LNEAL, CPRGVNP, MGGTWA, LTCDDP, VCNYRDV, QPLAPLVG, and DINGFLPAL. The invention provides for administration of the peptide prior to and following exposure of the subject to a source of radiation.
摘要翻译：治疗有需要的受试者的放射线损伤的方法包括向受试者施用由VVC，LAG，AQG，LQGV，QVVC，MTRV，LAGV，LQAV，PGCP，VGQL， RVLQ，EMFQ，AVAL，FVLS，NMWD，LCFL，FSYA，FWVD，AFTV，LGTL，QLLG，YAIT，APSL，ITTL，QALG，GVLC，NLIN，SPIE，LNTI，LHNL，CPVQ，EVVR，MTEV，EALE，EPPE， LGTL，VGGI，RLPG，LQGA，LCFL，TLAVE，VEGNL，LNEAL，CPRGVNP，MGGTWA，LTCDDP，VCNYRDV，QPLAPLVG和DINGFLPAL。本发明提供了在受试者暴露于辐射源之前和之后对肽的施用。

2. 发明申请

US20090291901A1 Control of radiation injury 有权
标题翻译：辐射伤害控制
公开(公告)号：US20090291901A1
公开(公告)日：2009-11-26
申请号：US12460317
申请日：2009-07-15
申请人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
发明人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
IPC分类号： A61K38/06 , A61K38/07 , A61K38/08
CPC分类号： A61K9/0019 , A61K38/08
摘要： The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides a method of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids. Furthermore, the invention provides use of a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from radiation injury. In particular, the invention provides anti-radiation peptides having a dose reduction factor (DRF) against acute gamma irradiation of at least 1.10, said DRF determinable by testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a test group of mice treated with said peptide at 72 hours after WBI and, testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a control group of mice treated only with the vehicle of said peptide at 72 hours after WBI and wherein the DRF is calculated by dividing the LD50/30 of the peptide-treated animals by the LD50/30 of the vehicle-treated animals.
摘要翻译：本发明涉及由暴露于高能电磁波（X射线，γ射线）或颗粒（α粒子，β粒子，中子）引起的针对急性辐射伤害的药物开发领域。迄今为止，意外暴露于电离辐射后，没有有效的药物可以改善放射性损伤。本发明提供了治疗有需要的受试者的放射线损伤的方法，其包括对受试者施用小于30个氨基酸的肽或其功能类似物或衍生物。此外，本发明提供了小于30个氨基酸的肽或其功能类似物或衍生物用于生产用于治疗患有或相信患有辐射损伤的受试者的药物组合物的用途。特别地，本发明提供了抗辐射肽，其具有针对至少1.10的急性γ辐射的剂量减少因子（DRF），所述DRF可通过测定哪种剂量的辐射在30天（LD50 / 30）后导致50％死亡率（LD 50/30）在WBI后72小时用所述肽处理的小鼠的全身辐射（WBI）中，在全身辐射（WBI）后30天（LD50 / 30）的50％死亡率测定，在WBI后72小时只用所述肽载体处理的小鼠的对照组，其中通过将经肽处理的动物的LD 50/30除以载体处理的动物的LD50 / 30计算DRF。

3. 发明授权

US07795226B2 Control of radiation injury 有权
标题翻译：辐射伤害控制
公开(公告)号：US07795226B2
公开(公告)日：2010-09-14
申请号：US11715314
申请日：2007-03-07
申请人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
发明人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
IPC分类号： A61K38/07 , A61K38/04
CPC分类号： A61K9/0019 , A61K38/08
摘要： Methods of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide consisting of the amino acid sequence AQGV. The invention provides for administration of the amino acid composition prior to and following exposure of the subject to a source of radiation.
摘要翻译：治疗有需要的受试者的放射线损伤的方法包括向受试者施用由氨基酸序列AQGV组成的肽。本发明提供了在受试者暴露于辐射源之前和之后给予氨基酸组合物。

4. 发明申请

US20090281033A1 Control of radiation injury 审中-公开
公开(公告)号：US20090281033A1
公开(公告)日：2009-11-12
申请号：US12288935
申请日：2008-10-24
申请人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
发明人： Robbert Benner , Nisar Ahmed Khan , Richard Michael Carlton
IPC分类号： A61K38/16 , A61K38/10 , A61K38/08 , A61K38/07 , A61K38/06 , A61K38/05 , A61P43/00
CPC分类号： A61K9/0019 , A61K38/08
摘要： The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides a method of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids. Furthermore, the invention provides use of a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from radiation injury. In particular, the invention provides anti-radiation peptides having a dose reduction factor (DRF) against acute gamma irradiation of at least 1.10, said DRF determinable by testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a test group of mice treated with said peptide at 72 hours after WBI and, testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a control group of mice treated only with the vehicle of said peptide at 72 hours after WBI and wherein the DRF is calculated by dividing the LD50/30 of the peptide-treated animals by the LD50/30 of the vehicle-treated animals.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式